Condition: Familial Mediterranean Fever · FMF · Sponsor: R-Pharm International, LLC
The purpose of this study is to assess safety and efficacy of the long-term treatment with RPH-104 at doses of 80 or 160 mg once every 2 weeks (q2w) in patients with familial Mediterranean fever (FMF) with colchicine resistance or intolerance (i.e. colchicine resistant, crFMF), who completed the core study, during which they received at least one dose of RPH-104 (i.e. study patient population).
This description comes directly from the study's public registry record.
Yulia Karpova · +7 495 956 79 37 · jn.karpova@inbox.ru
Marina Beloukhova · +7 495 956 79 37 · beloukhova@partners.rpharm.ru
Always discuss trial participation with your own doctor first.
| Center of Medical Genetics and Primary Health Care LLC | Yerevan, Armenia | Recruiting |
| FSBEI HE First Moscow State Medical University named after I.M. Sechenov | Moscow, Russia | Recruiting |
| Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin | Moscow, Russia | Recruiting |
| Medical Technologies Ltd. | Saint Petersburg, Russia | Recruiting |
| Terafarm, Llc | Stavropol, Russia | Recruiting |
| Hacettepe University Faculty of Medicine | Ankara, Turkey (Türkiye) | Recruiting |
| Istanbul University Istanbul Faculty of Medicine | Istanbul, Turkey (Türkiye) | Recruiting |
| Istanbul University Cerrahpasa Faculty of Medicine | Istanbul, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05190991